

Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease

Peer-reviewed author version

Capodanno, Davide; Bhatt, Deepak L.; Eikelboom, John W.; Fox, Keith A. A.; Geisler, Tobias; Gibson, C. Michael; Ramon Gonzalez-Juanatey, Jose; James, Stefan; Lopes, Renato D.; Mehran, Roxana; Montalescot, Gilles; Patel, Manesh; Steg, P. Gabriel; Storey, Robert F.; VRANCKX, Pascal; Weitz, Jeffrey I.; Welsh, Robert; Zeymer, Uwe & Angiolillo, Dominick J. (2020) Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease. In: NATURE REVIEWS CARDIOLOGY, 17(4), p. 242-257.

DOI: 10.1038/s41569-019-0314-y

Handle: <http://hdl.handle.net/1942/30701>

## **Dual Thrombotic Pathway Inhibition for Secondary and Tertiary Prevention in Patients with Cardiovascular Disease**

Davide Capodanno, MD, PhD<sup>1</sup>, Deepak L. Bhatt, MD, MPH<sup>2</sup>, Christopher P. Cannon, MD<sup>2</sup>, John W. Eikelboom, MBBS, MSc, FRCPC<sup>3</sup>, Keith A. A. Fox, MB ChB, FRCP<sup>4</sup>, Tobias Geisler, MD<sup>5</sup>, C. Michael Gibson, MD<sup>6</sup>, Jose Ramon Gonzalez-Juanatey, MD, PhD<sup>7</sup>, Stefan James, MD<sup>8</sup>, Renato D. Lopes, MD, PhD<sup>9</sup>, Roxana Mehran, MD<sup>10</sup>, Gilles Montalescot, MD<sup>11</sup>, Manesh Patel, MD<sup>9</sup>, Ph Gabriel Steg, MD<sup>12</sup>, Robert F. Storey, MD<sup>13</sup>, Pascal Vranckx, MD, PhD<sup>14</sup>, Jeffrey I. Weitz, MD<sup>15</sup>, Robert Welsh, MD<sup>16</sup>, Uwe Zeymer, MD<sup>17</sup>, Dominick J. Angiolillo, MD, PhD<sup>18</sup>

1. Division of Cardiology, C.A.S.T., P.O. "G. Rodolico," Azienda Ospedaliero-Universitaria "Policlinico-Vittorio Emanuele", University of Catania, Catania, Italy.
2. Brigham and Women's Hospital Heart and Vascular Center, Harvard Medical School, Boston, MA, USA.
3. Population Health Research Institute, Hamilton General Hospital and McMaster University, Hamilton, Canada.
4. Centre for Cardiovascular Science, University of Edinburgh, Edinburgh United Kingdom.
5. Dept. of Cardiology and Angiology, University Hospital of Tübingen, Tübingen, Germany.
6. Cardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical, Harvard Medical School, Massachusetts
7. Cardiology Department, University Hospital, Santiago de Compostela, Spain. IDIS; CIBERCV.
8. Dept. of Medical Sciences and Uppsala Clinical research center, Uppsala University, Uppsala, Sweden.
9. Division of Cardiology, Duke Clinical Research Institute, Duke University, Durham, NC. USA.
10. Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, USA.
11. Sorbonne Université, ACTION Study Group, Institut de Cardiologie, Pitié Salpêtrière Hospital (AP-HP), Paris, France.
12. Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, Paris and Paris Diderot University, Sorbonne Paris Cité, FACT (French Alliance for Cardiovascular Trials, an F-CRIN network), INSERM U1148, Paris, France.
13. Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, United Kingdom.
14. Department of Cardiology and Critical Care Medicine, Hartcentrum Hasselt, and faculty of Medicine and Life Sciences at the University of Hasselt, Hasselt, Belgium.
15. Departments of Medicine and Biochemistry and Biomedical Sciences, McMaster University and the Thrombosis and Atherosclerosis Research institute, Hamilton, Ontario, Canada.
16. Cardiac Sciences Department, Mazankowski Alberta Heart Institute and University of Alberta, Edmonton, Alberta, Canada.
17. Klinikum Ludwigshafen and Institut für Herzinfarktforschung, Ludwigshafen, Germany.
18. Division of Cardiology, University of Florida College of Medicine, Jacksonville, FL, USA.

**Manuscript Text Word Count:** 7290

**Figures:** 7

**Tables:** 2

**References:** 94

### **Correspondence to:**

Dominick J. Angiolillo, MD, PhD  
University of Florida College of Medicine-Jacksonville  
655 West 8th Street  
Jacksonville, Florida, 32209  
Tel: +1-904-244-3933  
Fax: +1-904-244-3102  
E-mail: [dominick.angiolillo@jax.ufl.edu](mailto:dominick.angiolillo@jax.ufl.edu)

## Affiliations and Disclosures

**Dominick J. Angiolillo, MD, PhD** – Division of Cardiology, University of Florida College of Medicine, Jacksonville, FL, USA.

DJA declares that he has received consulting fees or honoraria from Amgen, Aralez, AstraZeneca, Bayer, Biosensors, Boehringer Ingelheim, Bristol-Myers Squibb, Chiesi, Daiichi-Sankyo, Eli Lilly, Haemonetics, Janssen, Merck, PhaseBio, PLx Pharma, Pfizer, Sanofi, and The Medicines Company and has received payments for participation in review activities from CeloNova and St Jude Medical. D.J.A. also declares that his institution has received research grants from Amgen, AstraZeneca, Bayer, Biosensors, CeloNova, CSL Behring, Daiichi-Sankyo, Eisai, Eli Lilly, Gilead, Idorsia, Janssen, Matsutani Chemical Industry Co., Merck, Novartis, Osprey Medical, and Renal Guard Solutions; in addition, Dominick J. Angiolillo is recipient of a funding from the Scott R. MacKenzie Foundation and the NIH/NCATS Clinical and Translational Science Award to the University of Florida UL1 TR000064 and NIH/NHGRI U01 HG007269, outside the submitted work.

**Deepak L. Bhatt, MD, MPH** - Brigham and Women's Hospital Heart and Vascular Center, Harvard Medical School, Boston, MA, USA.

DLB discloses the following relationships - Advisory Board: Cardax, Cereno Scientific, Elsevier Practice Update Cardiology, Medscape Cardiology, PhaseBio, Regado Biosciences; Board of Directors: Boston VA Research Institute, Society of Cardiovascular Patient Care, TobeSoft; Chair: American Heart Association Quality Oversight Committee; Data Monitoring Committees: Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute, for the PORTICO trial, funded by St. Jude Medical, now Abbott), Cleveland Clinic (including for the ExCEED trial, funded by Edwards), Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine (for the ENVISAGE trial, funded by Daiichi Sankyo), Population Health Research Institute; Honoraria: American College of Cardiology (Senior Associate Editor, Clinical Trials and News, ACC.org; Vice-Chair, ACC Accreditation Committee), Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute; RE-DUAL PCI clinical trial steering committee funded by Boehringer Ingelheim; AEGIS-II executive committee funded by CSL Behring), Belvoir Publications (Editor in Chief, Harvard Heart Letter), Duke Clinical Research Institute (clinical trial steering committees), HMP Global (Editor in Chief, Journal of Invasive Cardiology), Journal of the American College of Cardiology (Guest Editor; Associate Editor), Medtelligence/ReachMD (CME steering committees), Population Health Research Institute (for the COMPASS operations committee, publications committee, steering committee, and USA national co-leader, funded by Bayer), Slack Publications (Chief Medical Editor, Cardiology Today's Intervention), Society of Cardiovascular Patient Care (Secretary/Treasurer), WebMD (CME steering committees); Other: Clinical Cardiology (Deputy Editor), NCDR-ACTION Registry Steering Committee (Chair), VA CART Research and Publications Committee (Chair); Research Funding: Abbott, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Chiesi, CSL Behring, Eisai, Ethicon, Forest Laboratories, Idorsia, Ironwood, Ischemix, Lilly, Medtronic, PhaseBio, Pfizer, Regeneron, Roche, Sanofi Aventis, Synaptic, The Medicines Company; Royalties: Elsevier (Editor, Cardiovascular Intervention: A Companion to Braunwald's Heart Disease); Site Co-Investigator: Biotronik, Boston Scientific, St. Jude Medical (now Abbott), Svelte; Trustee: American College of Cardiology; Unfunded Research: FlowCo, Fractyl, Merck, Novo Nordisk, PLx Pharma, Takeda.

**Christopher P. Cannon, MD** - Brigham and Women's Hospital Heart and Vascular Center, and Harvard Medical School, Boston, MA, USA.

CPC has received research grants from Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi-Sankyo, Janssen, and Merck; and consulting fees from Alnylam, Amarin, Amgen,

Boehringer Ingelheim, Bristol-Myers Squibb, Eisai, Janssen, Kowa, Merck, Pfizer, Regeneron, and Sanofi.

**Davide Capodanno, MD, PhD** - Division of Cardiology, C.A.S.T., P.O. “G. Rodolico,” Azienda Ospedaliero-Universitaria “Policlinico-Vittorio Emanuele”, University of Catania, Catania, Italy. DC discloses the following relationships: speakers’ honoraria from Bayer, AstraZeneca, Daiichi Sankyo, Pfizer, Boehringer Ingelheim, and consulting fees from Abbott Vascular, Bayer and Daiichi Sankyo.

**John W. Eikelboom, MBBS, MSc, FRCPC** – Population Health Research Institute, Hamilton General Hospital and McMaster University, Hamilton, Canada. JWE holds a mid-career award from the Heart and Stroke Foundation of Ontario and the Jack Hirsh/Population Health Research Institute Chair in Thrombosis and Atherosclerosis. He has received honoraria and research support from AZ, Bayer, BI, BMS, Daiichi, Janssen, Pfizer and Servier.

**Keith A. A. Fox, MB ChB, FRCP** - Centre for Cardiovascular Science, University of Edinburgh, Edinburgh United Kingdom. KAAF discloses the following relationships: Grants Bayer/Janssen and AstraZeneca. Speaker engagements and consulting fees: Bayer/Janssen, Sanofi/Regeneron, Verseon.

**Tobias Geisler, MD** - Dept. of Cardiology and Angiology, University Hospital of Tübingen, Tübingen, Germany. TG discloses the following relationships: Speaker fees from AstraZeneca, Bayer AG, Bristol Myers Squibb/Pfizer, Daiichi Sankyo and Boehringer Ingelheim. Institutional research grants from Bayer AG, Bristol Myers Squibb/Pfizer and Daiichi Sankyo. TG is recipient of funding from the DFG (German Research Foundation) Klinische Forschergruppe 274—Platelets—Molecular Mechanisms and Translational Implications and the Collaborative Research Center Transregio 240.

**C. Michael Gibson, MD** - Cardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical, Harvard Medical School, Massachusetts. CMG reports being chief executive officer of the Baim Institute for Clinical Research, in addition to receiving research grant funding from Angel Medical Corp, Bayer Corp, CSL Behring, Janssen Pharmaceuticals, Johnson & Johnson Corp, and Portola Pharmaceuticals; consultant fees from Amarin Pharama, Amgen, Bayer Corp, Boehringer Ingelheim, Boston Clinical Research Institute, Boston Scientific, Cardiovascular Research Foundation, CSL Behring, Chiesi, Duke Clinical Research Institute, Eli Lilly and Company, Gilead Sciences, Inc, Impact Bio LTD, Janssen Pharmaceuticals, Johnson & Johnson Corp, The Medicines Company, MedImmune, Medtelligence, Merck & Co, Inc, Microport, Novo Nordisk, PERT Consortium, Pharma Mar, Portola Pharmaceuticals, Sanofi, Somahlution, Vereseon Corporation, and Web MD; and royalties as a contributor from *UpToDate in Cardiovascular Medicine*.

**Jose Ramon Gonzalez-Juanatey, MD, PhD** - Cardiology Department, University Hospital, Santiago de Compostela, Spain. IDIS; CIBERCV. JRGJ has received institutional research funding from Angem, AstraZeneca, Bayer, Boehringer-Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Ferrer International, Medtronic, MDS, Novartis, Pfizer, Sanofi, Servier; is a consultant to Bayer, Boehringer-Ingelheim, Amgen.

**Stefan James, MD** - Dept. of Medical Sciences and Uppsala Clinical research center, Uppsala University, Uppsala, Sweden.

SJ has received institutional research grants and speaker honoraria from Astra Zeneca, Jensen, Bayer, The Medicines Company, Boeringer-Ingelheim, Amgen, Novo Nordisk, Abbot vascular, Boston Scientific, Biotronik.

**Renato D. Lopes, MD, PhD** -Duke Clinical Research Institute, Duke Health, Durham, NC, USA. RDL has received consulting fees from Amgen, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Medtronic, Pfizer, and Sanofi; and has received institutional grants from Bristol-Myers Squibb, GlaxoSmithKline, Medtronic, Pfizer, and Sanofi.

**Roxana Mehran, MD** - Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, USA.

RM has received institutional research funding from AstraZeneca, Bayer, Beth Israel Deaconess, Bristol-Myers Squibb/Sanofi, CSL Behring, Eli Lilly/Daiichi Sankyo, Medtronic, Novartis and OrbusNeich; is a consultant to Boston Scientific, Abbott Vascular, Medscape, Siemens Medical Solutions, Regeneron Pharmaceuticals Inc. (no fees), Roivant Sciences Inc, and Sanofi; is an institutional consultant (payment to institution) with Abbott Vascular and Spectranetics/Phillips/Volcano Corporation; is on executive committee for Janssen Pharmaceuticals, BMS, and receives institutional (payment to institution) advisory board funding from Bristol Myers Squibb; Novartis, and DSMB membership funding to institution from Watermark Research; has <1% equity with Claret Medical and Elixir Medical.

**Gilles Montalescot, MD** - Sorbonne Université, ACTION Study Group, Institut de Cardiologie, Pitié Salpêtrière Hospital (AP-HP), Paris, France.

GM reports research Grants to the Institution or Consulting/Lecture Fees from Abbott, Amgen, Actelion, American College of Cardiology Foundation, AstraZeneca, Axis-Santé, Bayer, Boston-Scientific, Boehringer Ingelheim, Bristol-Myers Squibb, Beth Israel Deaconess Medical, Brigham Women's Hospital, China heart House, Daiichi-Sankyo, Idorsia, Elsevier, Europa, Fédération Française de Cardiologie, ICAN, Lead-Up, Medtronic, Menarini, MSD, Novo-Nordisk, Partners, Pfizer, Quantum Genomics, Sanofi, Servier, WebMD.

**Manesh Patel, MD** – Division of Cardiology, Duke Clinical Research Institute, Duke University, Durham, NC. USA.

MRP reports research grants to the Institution from AstraZeneca, Bayer, Janssen, NIH, Procyron, Heartflow, Medtronic, Consulting/Advisory Board fees from Bayer, Janssen, Medscape, and Amgen.

**Ph Gabriel Steg, MD** – Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, Paris and Paris Diderot University, Sorbonne Paris Cité, FACT (French Alliance for Cardiovascular Trials, an F-CRIN network), INSERM U1148, Paris, France.

PGS discloses the following relationships: research grant from Amarin, Bayer, Merck, Sanofi, and Servier; speaking or consulting fees from Amarin, Amgen, AstraZeneca, Bayer/Janssen, Boehringer-Ingelheim, Bristol-Myers-Squibb, Idorsia, Lilly, Merck, Novartis, Novo-Nordisk, Pfizer, Regeneron, Sanofi, Servier.

**Robert F. Storey, MD** – Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, United Kingdom.

RFS reports research grants to the institution from AstraZeneca and PlaqueTec; consultancy fees from Amgen, AstraZeneca, Bayer, Bristol Myers Squibb/Pfizer, GlyCardial, Haemonetics, Idorsia, Novartis, PlaqueTec and Thromboserin; and speaker fees/honoraria from AstraZeneca, Bayer, Bristol Myers Squibb/Pfizer and Medscape.

**Pascal Vranckx, MD, PhD** - Department of Cardiology and Critical Care Medicine, Hartcentrum Hasselt, and faculty of Medicine and Life Sciences at the University of Hasselt, Hasselt, Belgium. PV has received personal fees from AstraZeneca, Bayer HealthCare, CLS Behring, and Daiichi-Sankyo. ~~Dr. Lopes has received consulting fees from Amgen, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Medtronic, Pfizer, and Sanofi; and has received institutional grants from Bristol Myers Squibb, GlaxoSmithKline, Medtronic, Pfizer, and Sanofi.~~

**Jeffrey I. Weitz, MD** - Departments of Medicine and Biochemistry and Biomedical Sciences, McMaster University and the Thrombosis and Atherosclerosis Research institute, Hamilton, Ontario, Canada. JIW has received institutional research funding from Bayer and Boehringer-Ingelheim and consultant fees and honoraria from Bayer, Boehringer-Ingelheim, Bristol-Myers Squibb, Daiichi-Sankyo, Pfizer, Portola, Ionis Pharmaceuticals, Janssen, Servier, Anthos, and Tetherex.

**Robert Welsh, MD** - Cardiac Sciences Department, Mazankowski Alberta Heart Institute and University of Alberta, Edmonton, Alberta, Canada. RW reports research grants and honoraria from Astra Zeneca, Bayer, and Boehringer Ingelheim. RW reports honoraria from Amgen, Bristol Meyers Squibb/Pfizer, and Eli Lilly.

**Uwe Zeymer, MD** - Klinikum Ludwigshafen and Institut für Herzinfarktforschung, Ludwigshafen, Germany. UZ reports research grants from Astra Zeneca, BMS, Novartis, Eli Lilly and speakers fees/honoraria from Abiomed, AstraZeneca, B. Braun, Biotronik, Boehringer Ingelheim, Bayer, BMS, Correio, Daiichi Sankyo, Eli Lilly, Ferrer, Medtronic, Medicines Company, MSD, Novartis, Pfizer, Sanofi, Trommsdorf.

## **ABSTRACT**

Advances in antiplatelet therapies for patients with cardiovascular disease have improved patients' outcomes over time, but the challenge of balancing ischemic and bleeding risks remains substantial. Because a residual risk of ischemic events exists in patients with cardiovascular disease despite being on antiplatelet therapy, there is a need for novel strategies that prevent clinical events via mechanisms that extend beyond platelet inhibition at an acceptable risk of bleeding. The advent of non-vitamin K antagonist oral anticoagulants, which attenuate fibrin formation by selective inhibition of factor Xa or thrombin, has refueled the interest in dual-pathway inhibition strategies that combine an antiplatelet agent with an anticoagulant. The objective of this review article is to illustrate the emerging pharmacological rationale and clinical development of dual-pathway inhibition for prevention of atherothrombotic events in patients with different manifestations of cardiovascular disease.

## KEY POINTS

- Aspirin has been the standard of care in the chronic atherosclerosis setting, where residual risk remains despite the availability of established therapies for limiting atherosclerosis progression and stabilizing existing plaques.
- Secondary and tertiary prevention with antithrombotic strategies that are not restricted to only aspirin is an emerging paradigm.
- The combination of antiplatelet drugs with low-dose rivaroxaban has proved effective in two large-scale randomized trials across the spectrum of atherosclerosis.
- While such strategy may be of clinical benefit in a broad group of individuals with coronary and peripheral artery disease, patient selection should leverage the baseline residual risk of ischemic events against the expected increased risk of bleeding.
- Whether a dual-pathway antithrombotic strategy for chronic atherosclerosis would be also effective by using other direct factor X inhibitors other than rivaroxaban (i.e., apixaban, edoxaban) is unknown.

## INTRODUCTION

Although advances in antiplatelet therapies for patients with cardiovascular disease have improved overall patient outcomes, balancing ischemic and bleeding risks remains challenging and substantial possibility of recurrent ischemic events remains after presentation with acute coronary syndromes and interventions.<sup>1-5</sup> In particular, in trials of patients with chronic vascular disease on high rates of contemporary therapies such as statins and angiotensin converting enzyme inhibitors, the risk of major adverse cardiovascular events at 1 year remains about 3%, with event rates even higher in real world contemporary practice.<sup>3-7</sup> (**Figure 1**) Therefore, there is a need for novel strategies that prevent clinical events via mechanisms that extend beyond platelet inhibition. The advent of non-vitamin K antagonist oral anticoagulants (NOACs), which attenuate fibrin formation by selective inhibition of factor Xa or thrombin, has refueled the interest in dual-pathway inhibition (DPI) strategies that combine an antiplatelet agent with an anticoagulant. The objective of this review article is to illustrate the emerging pharmacological rationale and clinical development of DPI for prevention of atherothrombotic events in patients with different manifestations of cardiovascular disease.

## VASCULAR BED INVOLVEMENT

Atherosclerosis is a chronic and progressive disease that begins early in life and typically becomes symptomatic in middle age. Typical locations of atherosclerosis include the coronary arteries, the carotid and cerebrovascular arteries, and the aorta and arteries of the lower limbs. In such vascular territories, atherosclerosis is the leading cause of coronary artery disease (CAD), cerebrovascular disease (CVD) and peripheral artery disease (PAD), respectively. Inflammatory and immune pathways are increasingly recognized as the link between cardiovascular risk factors (e.g., hypertension, dyslipidemia, diabetes, smoking) and atherosclerosis.<sup>8</sup> Atherosclerotic disease begins with subclinical states where the presence of underlying atherosclerosis may be suspected by the

presence of cardiovascular risk factors or established by means of imaging studies (e.g., Doppler ultrasound, coronary computed tomography, invasive imaging, PET imaging).<sup>9</sup> In later presentations, the presence of CAD, CVD or PAD may be symptomatic but not yet associated with an acute ischemic event (i.e., stable). Such patients may require elective or emergency revascularization, for example following an acute event such as a myocardial infarction (MI), stroke or acute limb ischemia. Because atherosclerosis is a systemic disease, many patients with known atherosclerotic disease in one vascular territory have subclinical or clinical involvement of other vascular beds. For example, in the REACH (Reduction of Atherothrombosis for Continued Health) registry, which included 67,888 patients with or at risk of CAD, CVD or PAD, 15.9% of patients had polyvascular disease.<sup>6</sup> The rate of ischemic events at 1 year increased from 5.3% for patients with risk factors only to 12.6%, 21.1% and 26.3% for patients with symptomatic involvement of 1, 2, and 3 arterial beds, respectively ( $P < 0.001$  for trend).<sup>7</sup>

### **Pathogenesis of atherothrombosis**

Thrombi are rich in platelets and stabilized by fibrin. Key platelet activation mechanisms are illustrated in **Figure 2**. Platelet adhesion is mediated by the interaction between platelet receptors and ligands exposed on the injured endothelium (e.g., collagen and von Willebrand factor). Platelet activation is promoted by soluble ligands (e.g., adenosine diphosphate, serotonin, thromboxane  $A_2$ , and thrombin), which interact with specific platelet membrane receptors (e.g., purinergic, 5-hydroxytryptamine 2A, thromboxane  $A_2$  receptor isoform  $\alpha$ , proteinase-activated receptors [PARs] 1 and 4). This process is amplified by the release of high concentrations of platelet agonists including adenosine diphosphate (ADP) stored in dense granules within the platelet which interacts with the platelet membrane P2Y purinoceptor 12 [P2Y<sub>12</sub>]. Platelet aggregation is achieved and further amplified by outside-in signaling predominantly through the interposition of fibrinogen between glycoprotein IIb/IIIa receptors located on the platelet membrane. Several antiplatelet drugs

block the phase of platelet activation by inhibition of thromboxane A<sub>2</sub> production by cyclooxygenase-1 (aspirin), inhibition of the phosphodiesterase 3 (cilostazol), inhibition of the P2Y<sub>12</sub> receptor (the oral drugs ticlopidine, clopidogrel, prasugrel and ticagrelor, and the intravenous drug cangrelor), inhibition of the PAR-1 receptor (vorapaxar), or inhibition of the 5-hydroxytryptamine 2A receptor (sarpogrelate and naftidofudryl) with different regulatory status and commercial availability across the world. Also, three intravenous drugs (abciximab, tirofiban, eptifibatide) block the final common pathway of platelet aggregation by targeting the glycoprotein IIb/IIIa receptor.

The coagulation cascade follows an extrinsic pathway, initiated by tissue injury, and an intrinsic pathway, characterized by contact activation. Both pathways converge with the activation of factor X, which, in association with factor Va, converts factor II (prothrombin) to factor IIa (thrombin). Thrombin amplifies its own generation through feedback activation of factors V, VIII and XI, activates factor XIII (or fibrin stabilizing factor) and is responsible for the conversion of fibrinogen (factor I) into fibrin (factor Ia), which contributes to clot formation and stabilization as described above. Several drugs are available that inhibit the coagulation cascade at different levels: the oral vitamin K antagonists (VKAs) [e.g., warfarin, phenprocoumon and acenocumarol (preventing the post-translational gamma carboxylation of thrombin, VII, IX, X)], the NOACs (dabigatran - inhibiting thrombin - and rivaroxaban, apixaban, edoxaban, betrixaban – inhibiting factor Xa), and parenteral agents (fondaparinux – inhibiting factor Xa -, unfractionated heparin, low molecular weight heparin and danaparoid – inhibiting thrombin and factor Xa -, bivalirudin and argatroban – inhibiting thrombin).

### **Goals of antithrombotic therapy and stages of vascular prevention**

In patients with CAD, CVD or PAD, acute ischemic events in most cases cause irreversible harm to an organ or vascular territory. The aim of antithrombotic therapy is to prevent the first or recurrent

atherothrombotic episodes, which are generally characterized by rupture of an atherosclerotic plaque with superimposition of a platelet-rich thrombus stabilized by a fibrin mesh.<sup>9</sup> In this context, antithrombotic drugs are given for primary, secondary or tertiary prevention (**Figure 3**). Of note, primary prevention aims to prevent CAD, CVD or PAD manifestations before they occur, secondary prevention strategies target individuals with established CAD, CVD or PAD who have not yet experienced an ischemic event or revascularization, and tertiary prevention aims to reduce the impact and sequelae of CAD, CVD or PAD manifestations that have already occurred. Notably, the difference between secondary and tertiary prevention is frequently overlooked, and patients with both subclinical or clinically apparent atherosclerosis are typically considered candidates to secondary prevention. However, it is different to incidentally discover an atherosclerotic plaque during a noninvasive examination (e.g., carotid ultrasound or coronary computed tomography) or after a clinical consequence (e.g. stroke or MI). Indeed, trials of atherothrombotic strategies often included patients in need of different levels of prevention, which complicates interpretation of their external generalizability. In addition, while many trials conducted in patients with atherosclerosis were performed in patients with clinical manifestations of CAD, CVD or PAD, scarce evidence has been produced for patients where the detection of atherosclerosis is at the subclinical stage. More research is therefore required to better understand how to treat exactly which kind of atherosclerotic manifestation.

### **Guideline recommendations for vascular prevention**

**Table 1** summarizes current European Society of Cardiology and American College of Cardiology/American Heart Association guidelines for use of antiplatelet therapy for primary, secondary and tertiary cardiovascular prevention.<sup>10–17</sup> Guidelines generally recommend against the use of antiplatelet therapy for primary prevention in patients without overt atherosclerotic disease. This recommendation is reinforced by the failure of recent trials to demonstrate sufficiently large

reductions in outcome events with aspirin versus placebo to counterbalance the risk of bleeding in this lower risk population.<sup>18-23</sup> The role of antiplatelet therapy for secondary prevention in patients with established CAD (e.g. incidentally detected at coronary angiography or coronary computed tomography but not necessarily causing ischemia) and with no history of a cardiovascular event is currently unclear but such strategy is prescribed in many patients. According to the 2019 guidelines for chronic coronary syndromes from the European Society of Cardiology, and based on consensus of task force members, aspirin may be considered in patients without a history of MI or revascularization but with definitive evidence of CAD on imaging.<sup>16</sup> In contrast, antiplatelet therapy is an established therapy for tertiary prevention. Thus, patients with acute coronary syndrome (ACS) or those who have undergone percutaneous coronary intervention (PCI) or coronary artery bypass grafting CABG benefit from a period of dual antiplatelet therapy (DAPT) followed by chronic use of single antiplatelet therapy (SAPT). The option of intensified antithrombotic therapy (e.g., DAPT or DPI instead of aspirin for selected patients) has entered the 2019 European guidelines for chronic coronary syndromes with a class IIa of recommendation for patients who are at low risk of bleeding and high ischemic risk (i.e., multivessel disease plus one of the following: diabetes, recurrent MI, PAD or chronic kidney disease) and a class IIb for patients who are at low risk of bleeding and moderate ischemic risk (i.e., multivessel disease, diabetes, recurrent MI, PAD or chronic kidney disease).<sup>16</sup> SAPT is recommended by the European Society of Cardiology for secondary prevention in patients with CVD or PAD, whereas SAPT or DAPT of variable duration is recommended for tertiary prevention. The American College of Cardiology/American Heart Association did not issue specific guidelines for secondary and tertiary prevention of CVD, while they recommend SAPT for secondary prevention in patients with PAD, and DAPT for selected patients after PAD revascularization.

## DPI: PHARMACOLOGICAL CONSIDERATIONS

DPI involves simultaneous blockade of two pathways of thrombus formation to gain synergistic benefits.<sup>24</sup> DPI differs from DAPT in that it combines an anticoagulant with a single antiplatelet agent rather than combining two antiplatelet agents. As noted above, thrombin is a key factor for both platelet activation and fibrin formation, as it serves both as a platelet agonist and as a crucial component of the coagulation cascade. In addition, thrombin has been implicated in modulating a number of inflammation pathways, supporting its contributing role towards atherogenesis and its thrombotic complications (**Figure 4**).<sup>25–27</sup> The interplay of thrombin in platelet activation and coagulation is schematized in **Figure 5**. The classic DAPT combination of aspirin and a P2Y<sub>12</sub> inhibitor targets two pathways of platelet activation, but activation can still occur through thrombin and other receptors. In humans, four PARs (PAR-1, PAR-2, PAR-3 and PAR-4) have been identified on several types of cells.<sup>28</sup> PAR-1 and PAR-4 are expressed on human platelets and are rapidly activated by thrombin (**Figure 6**).<sup>26,27</sup> Thrombin generation is increased in patients with atherosclerotic disease manifestations compared to those without.<sup>29,30</sup> Reducing the concentration of thrombin by use of an anticoagulant has been proposed as a mechanism to inhibit clot formation through both its direct anticoagulant and indirect antiplatelet effects with rivaroxaban being the only agent investigated for this strategy to date (e.g., rivaroxaban at the 2.5 mg bid dose + low dose aspirin and rivaroxaban 5.0 mg bid alone).<sup>24</sup> In combination with aspirin, this effect points towards synergistic benefits in reducing thrombus formation. In a pig model, rivaroxaban reduced the weight of experimentally-induced stent thrombus by 66% versus that in controls, and the effect was dose-dependent, which suggests some degree of thrombin-mediated antithrombotic efficacy.<sup>31</sup> However, adding rivaroxaban to aspirin yielded an 86% reduction in thrombus weight, and rivaroxaban in combination with DAPT suppressed in-stent thrombus formation by 98%.<sup>31</sup> By contrast, the reduction in thrombus formation with DAPT alone was 79%.<sup>31</sup> In vitro investigations have confirmed that rivaroxaban inhibits thrombin generation in a concentration-dependent manner, an effect synergistically enhanced with the addition of ticagrelor or DAPT with ticagrelor and

aspirin.<sup>32</sup> Rivaroxaban alone has shown to increase fibrinolysis on in vitro models, through activation and enhanced secretion of urokinase plasminogen activator from endothelial cells, a mechanism which could help to reduce the thrombi, and also reduced the adhesion of platelets to endothelial cells.<sup>33</sup> In aggregate, these data support that the effects of rivaroxaban are complementary to ADP receptor blockade by means of P2Y<sub>12</sub> inhibitors and COX-1 inhibition by means of aspirin. Moreover, their synergistic effects support the potential for their combination for clinical use.

## **LONG-TERM DPI IN PATIENTS WITH CAD**

### **Lessons from studies of VKAs in CAD**

The strategy of DPI by combining a VKA with an antiplatelet in patients with CAD and no pre-existing indication to oral anticoagulation (OAC) was never adopted in clinical practice, despite some evidence supporting its efficacy. In a meta-analysis of 14 studies comparing DPI with VKA and aspirin versus aspirin alone, including 25,307 patients who recovered from an ACS, DPI did not affect the risk of major adverse events at a follow-up ranging between 3 months and 5 years (odds ratio [OR] 0.96, 95% confidence interval [CI] 0.90-1.03, P=0.30).<sup>34</sup> However, it did so in patients with a therapeutic international normalized ratio (INR) between 2 and 3 (OR 0.73, 95% CI 0.63-0.84), p<0.0001).<sup>34</sup> Therefore, the strategy of lowering the intensity of anticoagulation therapy by targeting a lower INR to enable a safer combination with antiplatelet agents does not seem to be effective. On the other hand, in patients with a therapeutic INR, the risk of major bleeding was increased by 2.3-fold, but the risk of intracranial bleeding was not increased. No mortality benefit was noted, possibly because the bleeding risk counteracted the observed decrease in MI. Importantly, these data come from studies conducted approximately 15 to 20 years ago, where DAPT was not the control comparison and the doses of aspirin ranged between 75 mg and 325 mg

per day. However, they highlight the benefit of adding an oral anticoagulant on top of aspirin, at the price of increased bleeding.

### **Lessons from studies of NOACs in atherosclerotic vascular disease**

*Acute coronary syndromes* – NOACs are now considered more than just alternatives to warfarin, because of their favorable safety profile, in particular reduced intracranial hemorrhage, demonstrated in several clinical scenarios, including atrial fibrillation (AF).<sup>35,36</sup> A number of phase 2 placebo-controlled trials have explored the potential of DPI with different NOACs for ACS patients on aspirin and with no baseline indication for OAC. The direct thrombin inhibitor ximelagatran showed promise in ACS patients in the ESTEEM (Efficacy and Safety of Oral Direct Thrombin Inhibitor Ximelagatran in Patients With Recent Myocardial Damage) trial, with no increase in bleeding and a significant reduction in ischaemic events.<sup>37</sup> However, this combination has not been further investigated because the drug was withdrawn from the market (or the applications for marketing approval discontinued in some countries) after reports of hepatotoxicity. DPI with escalating doses of dabigatran (50 mg to 150 mg twice daily), another direct thrombin inhibitor, was investigated in the RE-DEEM (RandomizEd Dabigatran Etexilate Dose Finding Study in Patients With Acute Coronary Syndromes Post Index Event With Additional Risk Factors for Cardiovascular Complications Also Receiving Aspirin and Clopidogrel: Multicentre, Prospective, Placebo Controlled, Cohort Dose Escalation Study) trial. When used on top of DAPT in patients with a recent MI, dabigatran produced a dose-dependent increase in bleeding events and a significant reduction in coagulation activity.<sup>38</sup> Because there were no signals of ischemic benefit (although the trial was not powered for efficacy), testing of dabigatran for the ACS indication never progressed to phase 3. Two more phase 2 trials of the factor X inhibitors darexaban and letaxaban showed a dose-dependent increase in bleeding with no apparent ischaemic benefits in the RUBY-1 (Study Evaluating Safety, Tolerability and Efficacy of YM150 in Subjects With Acute Coronary

Syndromes) and AXIOM-ACS (Phase 2 study of TAK-442, an oral factor Xa inhibitor, in patients following acute coronary syndrome) trials. Consequently, further development of these drugs was abandoned.<sup>39,40</sup> The only NOACs with satisfactory results in phase 2 investigations whose clinical development progressed to phase 3 ACS trials are the factor Xa inhibitors apixaban and rivaroxaban.

Escalating doses of apixaban were tested in the APPRAISE-1 (Apixaban for Prevention of Acute Ischemic and Safety Events) trial, where 1,715 patients with recent ACS on aspirin or DAPT were investigated.<sup>41</sup> Randomization to the two higher doses of apixaban (10 mg bid and 20 mg od) was discontinued upon recommendation of the data safety monitoring board due to excess bleeding.<sup>41</sup> The 2.5 mg bid and 10 mg od doses of apixaban resulted in dose-dependent increases in major or clinically-relevant non-major bleeding and numerically lower rates of ischemic events compared with placebo.<sup>41</sup> In the subsequent APPRAISE-2, the 5 mg bid dose and 2.5 mg bid dose for those with estimated creatinine clearance less than 40 ml/min (8.5% of trial) were evaluated.<sup>42</sup> The trial was stopped early after only 7,392 patients were randomized due to an increase in major bleeding with apixaban (hazard ratio [HR] 2.59, 95% CI 1.50-4.46, P=0.001), including intracranial and fatal bleeding, with no apparent reduction in ischemic events at a median follow-up of 241 days (HR 0.95, 95% CI 0.80-1.11, P=0.51). Notably, APPRAISE-2 used a combination of DAPT and the full dose of apixaban as used in trials of atrial fibrillation. This strategy increased the risk of severe bleeding with no added benefit.

Rivaroxaban is so far the only NOAC with successful testing of a DPI strategy in a phase 3 trial of ACS. In ATLAS ACS-TIMI 46 (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome–Thrombolysis in Myocardial Infarction 46), an earlier phase 2 investigation of 3,491 patients with stabilized ACS mostly on DAPT, the risk of clinically significant bleeding with rivaroxaban (at doses 5-20 mg given once daily or the same total daily dose given twice daily) versus placebo was increased in a

dose-dependent manner (HR 2.21, 95% CI 1.25-3.91 for 5 mg, HR 3.35, 95% CI 2.31-4.87 for 10 mg, HR 3.60, 95% CI 2.32-5.58 for 15 mg, and HR 5.06, 95% CI 3.45-7.42 for 20 mg doses;  $P<0.0001$ ).<sup>43</sup> In addition, the drug numerically reduced the main secondary efficacy endpoint of death, MI, or stroke (5.6% vs. 7.0%,  $P=0.10$ ).<sup>43</sup> The 2.5 mg and 5.0 mg bid doses showed the most favorable safety-efficacy profile and were accordingly selected for further testing in the phase 3 ATLAS ACS 2-TIMI 51, a double-blind, placebo-controlled trial of 15,526 patients with a recent ACS followed for a mean of 13 months and up to 31 months.<sup>44</sup> The primary efficacy end point, a composite of death from cardiovascular causes, MI or stroke, was reduced with rivaroxaban compared with placebo (8.9% vs. 10.7%, HR 0.84, 95% CI 0.74-0.96,  $P=0.008$ ), with improvement shown with both doses of rivaroxaban.<sup>44</sup> At variance with the higher dose, however, the lower dose of rivaroxaban reduced the rates of cardiovascular death and all-cause death.<sup>44</sup> The incidence of major bleeding (2.1% vs. 0.6%,  $P<0.001$ ) and intracranial hemorrhage (0.6% vs. 0.2%,  $P=0.009$ ) was increased with the two doses of rivaroxaban combined, while the incidence of fatal bleeding was not increased.<sup>44</sup> The 2.5 mg bid dose resulted in a lower incidence of fatal bleeding events than the 5 mg bid dose (0.1% vs. 0.4%,  $P=0.04$ ).<sup>44</sup> In a pooled analysis of 1,477 patients from the ATLAS ACS-TIMI 46 and ATLAS ACS 2-TIMI 51 trials, including post-ACS patients receiving aspirin monotherapy and randomized to either rivaroxaban 2.5 mg twice daily or rivaroxaban 5 mg twice daily or placebo, the composite of cardiovascular death, MI or stroke was reduced by the combined rivaroxaban group (2.5 or 5 mg BID) compared with placebo (HR 0.65, 95% CI=0.45–0.92,  $P=0.016$ ).<sup>45</sup> Although the combined rivaroxaban dose groups were associated with higher rates of major bleeding, the 2.5 mg dose group was not.<sup>45</sup> The safety of 2.5 mg bid rivaroxaban plus a P2Y<sub>12</sub> inhibitor (e.g., clopidogrel or ticagrelor) versus standard DAPT was tested in 3,037 patients with recent ACS in the GEMINI-ACS 1 (A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary Syndrome) trial.<sup>46</sup> Because all patients received a P2Y<sub>12</sub> inhibitor, this was essentially a comparison of the low dose of rivaroxaban with aspirin. Rates of major bleeding at 12

months were similar in the two groups (5% vs. 5%,  $P=0.58$ ).<sup>46</sup> Establishing the efficacy of DPI for ACS using the GEMINI-ACS 1 regimen, however, would require a larger trial powered for clinical endpoints.

***Percutaneous coronary intervention*** – Strategies of DPI have been the objective of several investigations in PCI patients with an indication for OAC, mostly due to AF.<sup>47</sup> In these trials, DPI was the consequence of combining antiplatelet therapy with pre-existing OAC rather than a strategy where an anticoagulant was added on top of background antiplatelet therapy. However, meaningful lessons on the safety of various regimens of DPI for PCI patients can be drawn from these studies. Of note, before contemporary trials of NOACs, a trial of VKA was performed. In the WOEST (What is the Optimal antiplatelet & Anticoagulant Therapy in Patients With Oral Anticoagulation and Coronary Stenting) trial, DPI with warfarin and clopidogrel led to a 64% relative decrease in bleeding episodes at 12 months compared with triple therapy with warfarin and DAPT, driven by a reduced rate of minor bleeding episodes.<sup>48</sup> In essence, the WOEST trial was a pivotal investigation in that it investigated the simplification of the reference “triple therapy” strategy by means of aspirin withdrawal. The pivotal findings from the WOEST trial set the foundations for trials of aspirin-free strategies using a NOAC (rivaroxaban, dabigatran, apixaban, and edoxaban) in patients with AF undergoing PCI.<sup>49</sup>

Trials of NOACs for PCI in patients with AF have been completed with rivaroxaban, dabigatran, apixaban and edoxaban. In the PIONEER AF-PCI (Open-Label, Randomized, Controlled, Multicenter Study Exploring Two Treatment Strategies of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy in Subjects with Atrial Fibrillation who Undergo Percutaneous Coronary Intervention) trial, two rivaroxaban-based DPI regimens (e.g., a WOEST-like strategy of 15 mg od rivaroxaban plus a single P2Y<sub>12</sub> inhibitor, and an ATLAS ACS 2-TIMI 51-like regimen of 2.5 mg bid rivaroxaban [2.5 mg bid] plus DAPT) resulted in 41% and 37% reduced risks of total bleeding events compared with triple-therapy DPI using warfarin and

DAPT.<sup>50</sup> Both rivaroxaban-based DPI regimens were also associated with a reduced risk of all-cause mortality or recurrent hospitalization for adverse events.<sup>51</sup> It is important to note that the dosing regimens of rivaroxaban tested in this trial are not approved for stroke prevention in AF.

In the RE-DUAL PCI (Randomized Evaluation of Dual Antithrombotic Therapy with Dabigatran versus Triple Therapy with Warfarin in Patients with Nonvalvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention) trial, compared with patients on triple-therapy with warfarin and DAPT, the risk of major or clinically relevant non-major bleeding at a mean of 14 months was reduced by 48% in the arm of patients on DPI with dabigatran 110 mg bid and clopidogrel and by 28% in the arm of patients on DPI with dabigatran 150 mg bid and clopidogrel.<sup>52</sup> Both PIONEER-AF PCI and RE-DUAL PCI were small and underpowered for ischemic endpoints, although in RE-DUAL PCI the risk of thromboembolic events was noninferior in the two dabigatran groups combined as compared with the reference group.<sup>52</sup>

In the AUGUSTUS (An open-Label, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo) trial, 4,614 patients with AF who had an ACS or had undergone PCI on average one week before were randomized two-by-two to apixaban or a VKA and to aspirin or placebo.<sup>53</sup> The primary outcome, a composite of major or clinically-relevant non-major bleeding at 6 months, was reduced by 31% with apixaban compared with VKA and increased by 89% with aspirin compared with placebo.<sup>53</sup> Patients in the apixaban arm had a lower incidence of death or hospitalization than those on VKA, and a similar incidence of ischemic events, while patients in the aspirin group had a similar incidence of death or hospitalization and of ischemic events compared with placebo.<sup>53</sup> Thanks to its multifactorial design, AUGUSTUS clarifies that dropping aspirin reduces the risk of bleeding on top of the bleeding risk reduction already achieved by the use of NOACs (apixaban) versus VKA.

Finally, in the ENTRUST-AF PCI (Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation),

compared with patients on triple-therapy with VKA and DAPT, DPI with edoxaban 60 mg od and a P2Y<sub>12</sub> inhibitor was noninferior (but not superior) with respect to the risk of major or clinically relevant non-major bleeding at 12 months.<sup>54</sup> Again, there were no differences in ischemic events, but the trial size was small.

In aggregate, PIONEER-AF PCI, RE-DUAL PCI, AUGUSTUS and ENTRUST-AF PCI highlight that DPI with a NOAC and a single antiplatelet agent (i.e., a P2Y<sub>12</sub> inhibitor, mostly clopidogrel) is a safer regimen than triple therapy, particularly when a VKA is used.<sup>55</sup> Moreover, in this context of AF patients undergoing PCI treated with a single antiplatelet agent, a NOAC should be used at the dosing regimen recommended for stroke prevention in order to allow adequate antithrombotic protection.<sup>56</sup> A meta-analysis of WOEST, ISAR TRIPLE, PIONEER-AF PCI, RE-DUAL PCI, encompassing 5,317 patients, showed a reduction in major or minor bleeding with dual-therapy DPI as compared with triple-therapy DPI, with comparable ischemic outcomes.<sup>57</sup> A subsequent meta-analysis including AUGUSTUS showed that dual-therapy DPI with NOACs reduces major bleeding and intracranial hemorrhage compared with triple-therapy DPI with VKAs.<sup>58</sup> A further updated meta-analysis of the four trials of NOACs in AF-PCI, including ENTRUST-AF PCI, highlighted a numerical trend towards an increased risk of stent thrombosis with dual-therapy DPI, which calls for careful weighing of thrombotic and bleeding risk at the time of establishing the optimal length of aspirin therapy in PCI patients on a NOAC and a P2Y<sub>12</sub> inhibitor.<sup>54,55</sup>

**Stable atherosclerotic vascular disease** – In the COMPASS (Cardiovascular Outcomes for People Using Anticoagulation Strategies) trial, two strategies using rivaroxaban (with and without aspirin) were compared with chronic aspirin use for secondary prevention in patients with a history of stable atherosclerotic vascular disease (e.g., CAD or PAD).<sup>59</sup> A total of 27,395 patients (90.6% with CAD, 27.3% with PAD) were randomized to rivaroxaban 2.5 bid plus aspirin, rivaroxaban 5 mg bid alone, or aspirin 100 mg alone. The prevalence of state-of-the-art medications for patients with stable atherosclerosis, such as lipid-lowering agents and angiotensin-converting–enzyme

inhibitors or angiotensin-receptor blockers was high. The trial was event-driven and anticipated to continue until 2,200 primary endpoint events occurred. However, the data safety monitoring board recommended stopping it earlier due to overwhelming proof of efficacy in the DPI arm (rivaroxaban plus aspirin). At a mean follow-up of 23 months, the primary efficacy outcome, a composite of cardiovascular death, stroke or MI occurred in 4.1% of patients in the DPI arm, in 4.9% of patients in the rivaroxaban-only arm, and in 5.4% of patients in the aspirin-alone arm (HR for DPI vs. aspirin 0.76, 95% CI 0.66-0.86,  $P < 0.001$ ; HR for rivaroxaban vs. aspirin 0.90, 95% CI 0.79-1.03,  $P = 0.12$ ). The benefit with DPI was driven by reductions in cardiovascular death and stroke, with no reduction in MI although it was numerically reduced.<sup>59</sup> Further scrutiny of stroke outcomes revealed that, compared with aspirin alone, DPI reduced ischemic/uncertain strokes by 49% and fatal/disabling stroke by 42%, while prior stroke represented the strongest predictor of incident stroke.<sup>60</sup> Overall, outcomes were consistent across pre-specified subgroups.

The safety outcome was major bleeding according to a modification of the International Society on Thrombosis and Haemostasis (ISTH) classification, which considered all bleeding that led to presentation to an acute care facility or hospitalization as major. Using this definition, major bleeding occurred more frequently in patients in the DPI arm than in those on aspirin alone (3.1% vs. 1.9%, HR 1.70, 95% CI 1.40-2.05,  $p < 0.001$ ), driven by bleeding (mostly gastrointestinal) that led to presentation to an acute care facility or hospitalization, with no differences in fatal bleeding or intracranial bleeding. The rate of major bleeding was higher with rivaroxaban alone than with aspirin. Overall, a net clinical benefit endpoint incorporating cardiovascular death, stroke, MI, fatal bleeding, or symptomatic bleeding into a critical organ was 20% lower with rivaroxaban plus aspirin than with aspirin, and not different between rivaroxaban alone and aspirin.<sup>59</sup>

In the COMPASS trial, 17,598 participants were further randomized to pantoprazole (40 mg daily,  $n = 8791$ ) or placebo ( $n = 8807$ ). At a median of 3 years, there was no statistically significant difference between the pantoprazole and placebo groups in safety events except for increased

enteric infections with pantoprazole.<sup>61</sup> Also, there was no significant difference in upper gastrointestinal events between groups (hazard ratio, 0.88; 95% confidence interval [CI], 0.67-1.15), but pantoprazole significantly reduced bleeding of gastroduodenal lesions (hazard ratio, 0.52; 95% confidence interval, 0.28-0.94; P = 0.03).<sup>62</sup>

In a post-hoc analysis of COMPASS, subsets of patients at higher risk of recurrent vascular events and best candidates to the DPI regimen were identified, including those with  $\geq 2$  vascular beds affected, heart failure, renal insufficiency, or diabetes.<sup>63</sup> Among patients with  $\geq 1$  high-risk feature identified from two different methodologies, DPI prevented 33 to 36 serious vascular events, whereas in lower-risk patients, DPI led to the avoidance of 10 to 11 events per 1,000 patients treated for 30 months. A further sub-analysis looked more specifically at patients with mild or moderate heart failure, where DPI produced similar relative but larger absolute benefits compared with patients without heart failure.<sup>64</sup> Another substudy of the overall COMPASS population showed that the benefits of DPI were preserved in patients with moderate renal dysfunction without evidence of an excess hazard of bleeding.<sup>65</sup>

In the COMPASS subgroup of patients with CAD (N=24,824), eligible patients had to have had a prior MI, multivessel CAD, history of stable or unstable angina, prior PCI or prior coronary artery bypass grafting (CABG).<sup>66</sup> DPI with rivaroxaban plus aspirin reduced the primary efficacy outcome by 26% (4% vs. 6%,  $p < 0.0001$ ) and all-cause mortality by 23% (3% vs. 4%,  $p < 0.0012$ ), but increased major bleeding by 66% compared with aspirin (3% vs. 2%,  $p < 0.0001$ ). Conversely, rivaroxaban alone was not associated with a significant benefit and increased bleeding by 51%.<sup>66</sup> In patients with a recent CABG (N=1,448), graft failure diagnosed by computed tomography at 1 year after surgery was not reduced with DPI.<sup>67</sup> In the COMPASS subgroup of patients with PAD (N=7,740), eligible patients had a history of PAD of the lower extremities (e.g., previous peripheral bypass surgery or angioplasty, limb or foot amputation, intermittent claudication with objective evidence of PAD), of the carotid (e.g., previous carotid artery revascularization or asymptomatic

carotid artery stenosis of at least 50%), or CAD with an ankle-brachial index less than 0.90.<sup>68</sup> DPI with rivaroxaban plus aspirin reduced the primary efficacy outcome by 28% (5% vs. 8%,  $p=0.0047$ ) and major adverse limb events including amputation by 46% (1% vs. 2%,  $p=0.0037$ ), at the price of a 61% increase in major bleeding (3% vs. 2%,  $p=0.0089$ ). Conversely, rivaroxaban alone did not reduce the primary efficacy endpoint, but reduced major adverse limb events including amputation by 33% and increased major bleeding by 140%. All-cause death did not change with both rivaroxaban strategies.<sup>68</sup> In the more restricted subgroup of 6,391 patients with lower extremity PAD (N=6,391), after a major limb event, the one year cumulative risks of a subsequent hospitalization, vascular amputation or death were 95.4%, 22.9%, and 8.7%, respectively.<sup>69</sup> DPI lowered the incidence of major limb events by 43% (1.5% vs. 2.6%,  $p=0.01$ ), total amputations by 58% (1.2% vs. 0.5%,  $p=0.01$ ) and peripheral vascular interventions by 24% (5.5% vs. 7.1%,  $p=0.03$ ) compared with aspirin alone.<sup>69</sup> In light of the observations from the COMPASS trial, the 2.5 mg bid dose of rivaroxaban has been labeled as the ‘vascular protection’ dose in order to differentiate it from dosing regimens used for other indications.

**Other clinical scenarios** - In patients with CAD and chronic heart failure, thrombin generation may contribute to disease progression by inducing inflammation, endothelial dysfunction, and arterial and venous thrombosis.<sup>70</sup> On this background, evaluation of DPI with rivaroxaban 2.5 mg bid was the objective of the placebo-controlled COMMANDER HF (A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction, or Stroke in Participants with Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure) trial. The study enrolled 5,022 patients with chronic heart failure, a left ventricular ejection fraction of 40% or less, CAD, and elevated plasma concentrations of natriuretic peptides (e.g., decompensated heart failure) who had recently been treated in hospital with an episode of worsening heart failure (within 21 days). The primary efficacy outcome - a composite of death from any cause, MI, or stroke - was not reduced with the DPI strategy, and safety outcomes were similar to placebo.<sup>71</sup> Indeed, rivaroxaban reduced the risk of thromboembolic

events, but these events were not the major cause of morbidity and mortality.<sup>72</sup> The difference between the results of COMMANDER-HF and the heart failure subgroup of COMPASS are therefore mostly explained from the different level of acute decompensation in the study populations. In fact, patients in COMPASS had mild or moderate heart failure, while those in COMMANDER-HF presented with more advanced pump failure.

The risk of ischemic events after transcatheter aortic valve replacement (TAVR) may depend on procedure- (e.g., device manipulation in the aorta), patient- (e.g. concurrent AF and/or CAD), and prostheses-related aspects (e.g., leaflet thrombosis). The choice of antithrombotic therapy after TAVR is evolving.<sup>73</sup> The GALILEO (Global Study Comparing a Rivaroxaban-Based Antithrombotic Strategy to an Antiplatelet-Based Strategy After Transcatheter Aortic Valve Replacement to Optimize Clinical Outcomes) trial tested a strategy of DPI with rivaroxaban 10 mg od and aspirin versus DAPT for 3 months in patients without a clinical indication for OAC, followed by drop of aspirin and clopidogrel in the two arms, respectively. Top line results of the trial have been reported, announcing early halting of the study due to increased mortality in the rivaroxaban arm.<sup>74</sup> Other trials are ongoing with apixaban in TAVR patients with and without baseline indication to OAC, and edoxaban in patients with baseline indication to OAC.<sup>75,76</sup>

## **DPI: STATUS AND CONSIDERATIONS**

***Acute coronary syndromes*** – The current standard of care for patients with ACS is DAPT for 12 months.<sup>77</sup> In 2012, the U.S. Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee voted against the approval of rivaroxaban for this indication, due to concerns surrounding safety as well as missing data on subjects who were lost to follow-up from the ATLAS ACS 2 trial, at variance with the European Medical Agency (EMA) that approved rivaroxaban one year later. Based on guidelines from the European Society of Cardiology, rivaroxaban 2.5 mg bid may be considered (class IIb, level of evidence B) after discontinuation of

parenteral anticoagulation in both patients with ST-segment elevation and non-ST-segment elevation MI patients with no prior stroke or transient ischemic attack and at high ischaemic risk as well as low bleeding risk receiving aspirin and clopidogrel.<sup>10,11</sup> Such a strategy has not found its way into routine clinical practice due to the higher perceived risk of bleeding in rivaroxaban-treated subjects who are already on DAPT and the availability of potent DAPT combinations with prasugrel or ticagrelor.<sup>78</sup>

**Percutaneous coronary intervention** – Patients undergoing elective PCI are recommended 6 months of DAPT, with options for prolonging or shortening DAPT based on the balance between the risks of thrombotic and bleeding complications.<sup>77</sup> There is currently no indication for DPI for patients with chronic CAD who receive a stent during the DAPT period and have no pre-existing indication for OAC, since these patients were excluded from the COMPASS trial although they were enrolled once DAPT was discontinued.<sup>59</sup> Conversely, DPI using antiplatelet agents and full-dose OAC is a standard therapy in PCI patients who need oral anticoagulation for concurrent reasons, including AF. Current recommendations from the United States for AF patients undergoing PCI are dated before the publication of the AUGUSTUS trial.<sup>79,80</sup> Conversely, current recommendations from Europe are dated after the publication of the AUGUSTUS trial but before the publication of ENTRUST-AF PCI.<sup>16</sup> The default approach recommended in the most recent North American consensus document is DPI with full dose NOAC and SAPT (e.g., clopidogrel).<sup>16,79–81</sup> The European guidelines assign the same class of recommendation (class IIa) for dual-therapy (with aspirin used in the periprocedural period and  $\leq 1$  week) and triple-therapy (e.g., using NOAC and DAPT for at least one month and up to 6 months depending on the thrombotic risk)<sup>16</sup> Dual-therapy is usually maintained up to 12 months, but shorter durations can be envisaged depending on the risk of bleeding. After 12 months from PCI or in patients with chronic CAD, the general recommendation is to maintain oral anticoagulation only and avoid DPI, which is currently corroborated by the results of two randomized trials (one stopped for low recruitment and the other due to increased mortality in the DPI arm) and one large-scale registry.<sup>82–84</sup>

**Stable atherosclerotic vascular disease** – SAPT with Flow-dose aspirin is the cornerstone for secondary and/or tertiary prevention in patients with chronic atherosclerotic vascular disease.<sup>77</sup> In 2018, rivaroxaban (2.5 mg bid) was approved by both the FDA and the EMA for patients with chronic CAD or PAD, and updated clinical guidelines with new recommendations for DPI in this context are anticipated. Whether a dual-pathway antithrombotic strategy for chronic atherosclerosis would be also effective by using other direct factor X inhibitors other than rivaroxaban (i.e., apixaban, edoxaban) is unknown. Likewise, it is uncertain whether the DPI strategy can be similarly effective when using a combination of rivaroxaban with clopidogrel rather than aspirin. One argument that can be reasonably raised in favour of aspirin for the DPI combination is that clopidogrel, the most commonly used P2Y<sub>12</sub> inhibitor, is not immune from a certain degree of interindividual variability in antiplatelet drug response with a considerable number of patients showing inadequate platelet inhibition hence at risk for thrombotic complications.<sup>85</sup> Therefore, keeping a patient on chronic clopidogrel-only could expose patients who are clopidogrel-resistant to the risk of being not protected at all. However, the CAPRIE trial suggests that the larger proportions of high on-treatment platelet resistance noted in pharmacodynamic studies of clopidogrel did not translate into significantly incremental risk on the ground of a large-scale clinical evaluation.<sup>2</sup>

On this background, the practical question is who are the ideal candidates for DPI therapy with aspirin and rivaroxaban? To address that question, it is useful to consider the inclusion and exclusion criteria for the COMPASS trial.<sup>86</sup> A study applying these criteria to 31,873 patients with CAD or PAD in the REACH registry found that 29.9% patients had exclusion criteria and an additional 17.2% did not fulfil the inclusion criteria and thus would not have been eligible for COMPASS.<sup>87</sup> The main reasons for exclusion were high-bleeding risk (51.8%), use of oral anticoagulation therapy (44.8%), requirement for DAPT within 1 year, ischemic stroke <1 year (12.4%), and severe renal failure (2.2%). As such, a substantial proportion of patients in the REACH registry (52.9%), which reflects a real-world cohort of candidates for secondary and tertiary prevention, would be theoretically eligible for the DPI regimen. Notably, these patients

experienced higher annualized primary outcome event rates than patients enrolled in the reference aspirin arm of COMPASS (4.2% vs. 2.9% per year,  $P < 0.001$ ), implying they would have likely also had greater benefit.<sup>87</sup> Another practical consideration is how DPI compares with other antithrombotic strategies in the CAD and PAD setting.<sup>86</sup> In patients with prior MI, ticagrelor 60 mg bid is approved for long-term DAPT, based on the results of the PEGASUS (Prevention with Ticagrelor of Secondary Thrombotic Events in High-Risk Patients with Prior Acute Coronary Syndrome) trial.<sup>4</sup> Because prior MI represented an inclusion criterion for COMPASS, a proportion of MI patients at low bleeding risk would be theoretically eligible for either DAPT or DPI (or SAPT as an alternative). In comparing the PEGASUS and COMPASS cohorts to reflect on the external generalizability of the trial results (**Table 2**), one should consider that, in PEGASUS, patients were included if they had a MI 1 to 3 years earlier (median 1.7 years), while in COMPASS patients were included up to 20 years from the MI (median 7 years). Also, prior stroke was an exclusion criterion in PEGASUS but not in COMPASS. Interestingly, the benefit of ticagrelor vs. placebo in PEGASUS was mostly confined to patients who were within 30 days of stopping the P2Y<sub>12</sub> inhibitor, while in both PEGASUS and COMPASS there was no interaction between the treatment effect of the investigational drug and the proximity of the MI. In aggregate, the two cohorts represent patients at different stages from the index event.<sup>86</sup> Candidates for the PEGASUS strategy may mostly benefit from uninterrupted DAPT after the recommended 12 month course of DAPT following the MI, and extending long-term as per the drug instructions for use, while candidates for the COMPASS strategy may be considered at any time after an MI. Importantly, PEGASUS excluded patients with any prior stroke, while in COMPASS only patients with a recent (<1 month) stroke or previous hemorrhagic or lacunar stroke were excluded. It should also be noted that the COMPASS trial results were driven by a reduction in cardiovascular death and stroke, while in PEGASUS the benefit was driven by a reduction in MI. These findings may suggest the differential role of DAPT compared with DPI on ischemic recurrences, with the former likely more effective on arterial thrombotic complications and the latter in cardioembolic events.<sup>86,88,89</sup> The differential

impact of these strategies on vascular inflammation and atherothrombotic complications cannot be excluded and warrants further investigation. A practical algorithm for the choice of antithrombotic treatment in patients with CAD, particularly after an MI, is provided in **Figure 7**.<sup>90</sup> Indeed, areas of needed investigation include understanding modalities and timing of switching from DAPT to DPI.

With respect to PAD, the COMPASS strategy enters an area where few antithrombotic options exist. In fact, the only evidence of a strategy superior to aspirin in PAD patients was that demonstrated in the CAPRIE (Clopidogrel Versus Aspirin in Patients at Risk of Ischemic Events) trial in which clopidogrel monotherapy reduced ischemic events compared with aspirin monotherapy in patients with stable vascular disease, a finding which was driven mostly by the PAD cohort.<sup>2</sup> However, more potent P2Y<sub>12</sub> inhibition with ticagrelor monotherapy failed to show any benefit over clopidogrel monotherapy.<sup>91</sup> Moreover, the benefit of a DAPT regimen over single antiplatelet treat in PAD patients is unclear and derives from small subgroup analysis.<sup>92,93</sup> Drugs such as cilostazol and naftidrofuryl are used to alleviate symptoms of limb ischemia. Ultimately, although adjunctive treatment with vorapaxar showed a reduction in hospitalization for acute limb ischemia and peripheral revascularization compared to standard of care therapy (aspirin and/or clopidogrel), this strategy did not reduce the primary composite ischemic endpoint and increased major bleeding, including intracranial hemorrhage, which contributes to explain its infrequent use in the countries where the drug is available.<sup>94</sup> Due to reduction in cardiovascular mortality, major limb adverse events and amputations, DPI may represent a major advance in the management of PAD.<sup>88</sup>

## CONCLUSIONS

Secondary and tertiary prevention with antithrombotic strategies that are not restricted to only aspirin is an emerging paradigm. The combination of antiplatelet drugs with low-dose rivaroxaban has proved effective in two large-scale randomized trials across the spectrum of atherosclerosis

(e.g., CAD and PAD patients from COMPASS and ACS patients from ATLAS-ACS 2). Such DPI strategy has been granted approval from regulatory authorities in both Europe (stable atherosclerosis and ACS) and the United States (stable atherosclerosis only), becoming available for clinical use. Aspirin has been the standard of care in the chronic atherosclerosis setting, where residual risk remains despite the availability of established therapies for limiting atherosclerosis progression and stabilizing existing plaques. The COMPASS trial shows that, on top of control of lipids, blood pressure and renin-angiotensin-aldosterone system blockade, rivaroxaban 2.5 mg bid plus aspirin reduced the composite endpoint of stroke, MI or cardiovascular death by 26% in CAD patients (stroke by 44%, cardiovascular death by 25%) and by 28% in PAD patients (major adverse limb events by 46%, major amputations by 70%). Despite an increase in major bleeding events with rivaroxaban 2.5 mg bid plus aspirin, there was no increase in fatal or critical organ bleeding. While DPI may be of clinical benefit in a broad group of individuals with CAD and PAD, patient selection for the COMPASS strategy should leverage the baseline residual risk of ischemic events against the expected increased risk of bleeding. Areas of uncertainty remain, which are the objective of future investigations. These include ascertaining the comparative efficacy and safety of DPI versus DAPT or even triple therapy in patients at high risk in whom the benefits would outweigh the bleeding risk.

## FIGURE LEGENDS

**Figure 1 – Residual risk of vascular events in trials of patients with chronic coronary artery disease (CAD) despite currently available medical therapy.** Data are shown for landmark studies of antithrombotic therapies for secondary and tertiary prevention with respect to the rates of major adverse cardiac events in the intervention and control groups. A mean residual risk of 3% is shown in most recent randomized trials. Data from references<sup>1–5</sup> Abbreviations: ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; MACE, major adverse cardiac events; NR, not reported.

**Figure 2 - Platelet activation mechanisms.** Platelet activation is initiated by soluble agonists, such as thrombin, thromboxane A<sub>2</sub> (TXA<sub>2</sub>), 5-hydroxytryptamine (5-HT), adenosine diphosphate (ADP), and adenosine triphosphate (ATP), and by adhesive ligands, such as collagen and von Willebrand factor (vWF). Consequently, dense granule secretion of platelet agonists and secretion of TXA<sub>2</sub>, as a result of phospholipase A<sub>2</sub> activation, lead to amplification of platelet activation and the associated responses. The P<sub>2</sub>Y purinoceptor 12 (P<sub>2</sub>Y<sub>12</sub>) receptor has a major role in the amplification of platelet activation, which is also supported by outside-in signaling via integrin  $\alpha$ IIb $\beta$ 3 (the glycoprotein IIb/IIIa receptor). Combined blockade of P<sub>2</sub>Y<sub>12</sub> and integrin  $\alpha$ IIb $\beta$ 3, therefore, has additive effects on platelet activation and the associated platelet responses. 5-HT<sub>2A</sub>, 5-HT receptor 2A; GPVI, platelet glycoprotein VI; NO, nitric oxide; PAR, proteinase-activated receptor; PGI<sub>2</sub>, prostacyclin receptor; TP $\alpha$ , TXA<sub>2</sub> receptor isoform  $\alpha$ . Reproduced with permission from <sup>49</sup>

**Figure 3 - Stages of cardiovascular prevention.** Primary prevention is aimed at preventing coronary artery disease (CAD), cerebrovascular disease (CVD) or peripheral artery disease (PAD), secondary prevention targets individuals with established CAD, CVD or PAD who have yet to

experience an ischemic event or undergo revascularization, and tertiary prevention is aimed at reducing the impact and sequelae of CAD, CVD or PAD that have already occurred. Abbreviations: ALI, acute limb ischemia; CV, cardiovascular; MI, myocardial infarction.

**Figure 4 - Overview of pathophysiology of atherothrombosis and the role of factor Xa and thrombin.** Dysregulation of endothelial cells forms the basis for the initial development of atherosclerosis. Atherosclerotic plaques subsequently develop through a complex inflammatory mediated process. Increased expression of adhesion molecules and release of proinflammatory cytokines by activated endothelial cells promotes recruitment of inflammatory cells. This process coupled with cell proliferation and accumulation of lipid deposits and foam cells favors atherosclerotic plaque growth. The sustained inflammation reduces plaque stability and promotes plaque rupture with thrombotic complications. Both factor Xa and thrombin contribute to the development of atherothrombosis. Abbreviations: F, factor; PAR, proteinase-activated receptor; SMC, smooth muscle cell. Reproduced with permission from <sup>26</sup>

**Figure 5 - Synergy of direct factor Xa inhibition and antiplatelet therapy.** Direct inhibitors of factor Xa, such as rivaroxaban, and antiplatelet agents, such as acetylsalicylic acid, synergistically target two essential components of atherothrombosis: coagulation and platelet activation. Inhibition of factor Xa modulates thrombin generation; thrombin is the most potent inducer of platelet activation and the prothrombinase complex on the platelet membrane is key generator of thrombin. Combination of rivaroxaban with antiplatelet agents works synergistically to reduce platelet activation, leading to the delayed/reduced formation of coagulation complexes and vice versa, thereby enhancing antithrombotic potency. COX1, cyclooxygenase 1; PAR, protease-activated receptor; P2Y<sub>12</sub>, P2Y purinoceptor 12; TXA<sub>2</sub>, thromboxane A<sub>2</sub>; TP $\alpha$ , TXA<sub>2</sub> receptor isoform  $\alpha$ .

**Figure 6 - Schematic representation of coagulation factor-mediated activation of PARs and cell types in which each PAR is expressed.** Four PARs (PAR-1–4) are expressed on the membranes of platelets and other cells. Thrombin (factor IIa) activates PAR-1, -3 and -4 (but not PAR-2). Factor Xa and TF–factor VIIa complex can each activate both PAR-1 and PAR-2. Once activated, factor Xa initiates intracellular signaling in various cell types of the cardiovascular system, preferentially mediated by PAR-2 or, when in ternary complex with tissue factor–FVIIa, through both PAR-1 and PAR-2. PAR-1, PAR-2, or both are present in abundance on endothelial cells, leukocytes, VSMCs, fibroblasts, and dendritic cells. Factor Xa–dependent, PAR-mediated signaling contributes to the production of proinflammatory cytokines (e.g., interleukin-6, interleukin-8, and chemokine ligand 2), and to the expression of cell-adhesion molecules (e.g., E-selectin, intracellular adhesion molecule 1 [ICAM-1], and vascular-cell adhesion molecule 1 [VCAM-1], along with tissue factor up-regulation, VSMC proliferation, and the release of growth factors (e.g., vascular endothelial growth factor, platelet-derived growth factor, and transforming growth factor  $\beta$ ). All these may contribute to the inflammatory process leading to atherosclerotic plaque **progression**. F, factor; PAR, proteinase-activated receptor; SMC, smooth muscle cell; TF, tissue factor. Reproduced with permission from<sup>27</sup>

**Figure 7. Choice of antithrombotic treatment strategy in patients with coronary artery disease.** Decision algorithm for DPI (e.g., aspirin plus rivaroxaban 2.5 mg bid) or prolonged DAPT (e.g., aspirin plus ticagrelor) in patients with stable CAD on aspirin monotherapy or patients with myocardial infarction and treated with DAPT, respectively. CABG, coronary artery bypass surgery; CAD, coronary artery disease; CKD, chronic kidney disease (eGFR < 60 mL/min and not requiring dialysis for prolonged DAPT; eGFR < 60 mL/min and > 15 mL/min for low dose rivaroxaban); DAPT, dual antiplatelet therapy; DM, diabetes mellitus; PAD, peripheral artery disease; MI: myocardial infarction. Reproduced from<sup>90</sup>

**Table 1 - Options for cardiovascular prevention with antiplatelet therapy for patients with CAD, CVD and/or PAD**

	Guidelines	CAD	CVD	PAD
Primary prevention	ESC	Antiplatelet therapy is generally not recommended		
	ACC/AHA			
Secondary prevention	ESC	SAPT may be considered in selected cases	SAPT with aspirin or clopidogrel	SAPT in symptomatic subjects
	ACC/AHA	Not covered	Not covered	SAPT is generally recommended in both symptomatic and asymptomatic subjects. Role of vorapaxar uncertain
Tertiary prevention	ESC	DAPT followed by SAPT immediately after an ACS, immediately after PCI and in the chronic phase after an MI	SAPT with aspirin or clopidogrel, or combination of aspirin and dipyridamole after a stroke or TIA; DAPT followed by SAPT immediately after CAS; SAPT after carotid surgery	DAPT followed by SAPT immediately after percutaneous revascularization; SAPT after surgical revascularization
	ACC/AHA		Not covered	DAPT reasonable immediately after revascularization.

Abbreviations: ACC, American College of Cardiology; ACS, acute coronary syndromes; AHA, American Heart Association; CAD, coronary artery disease; CAS, carotid artery stenting; CVD, cerebrovascular disease; DAPT, dual antiplatelet therapy; ESC, European Society of Cardiology;

MI, myocardial infarction; PAD, peripheral artery disease; PCI, percutaneous coronary intervention; SAPT, single antiplatelet therapy; TIA, transient ischemic attack.


**Table 2. Key difference between patients enrolled in the COMPASS and PEGASUS trials**

	<b>COMPASS</b>	<b>PEGASUS</b>
Inclusion criteria	CAD (prior MI <20 years earlier; multivessel CAD; multivessel PCI; CABG 4 to 14 days earlier); PAD (revascularization; amputation; claudication with ABI <0.9 or >50% stenosis; carotid revascularization or carotid stenosis >50%)	Prior MI 1 to 3 years earlier with at least one additional factor
Exclusion criteria	Previous lacunar stroke, previous ICH	Previous stroke, previous ICH, GI bleeding <6 months earlier
Age	68	65
Diabetes mellitus	38	32
Heart failure	21	NA
CrCl <60 ml/min	22%	23%
CAD	91%	100%
Multivessel disease	62%	59%
Previous MI	62% (median 7 yrs)	100% (median 1.7 yrs)
Previous PCI	60%	83%
PAD	27%	5%


Previous stroke	4%	-
Statin use	90%	92%
Beta-blocker use	70%	82%
ACEI/ARB use	71%	80%

Abbreviations: ABI, ankle-brachial index; ACEI, angiotensin converting enzyme inhibitors; ARB, angiotensin receptor blockers; CAD, coronary artery disease; CrCl, creatinine clearance; GI, gastrointestinal; ICH, intracranial hemorrhage; MI, myocardial infarction; PAD, peripheral artery disease; PCI, percutaneous coronary intervention.


**FIGURE 1**




**FIGURE 2**




**FIGURE 3**




**FIGURE 4**




**FIGURE 5**



**FIGURE 6**



**FIGURE 7**



## REFERENCES

1. Antithrombotic Trialists' (ATT) Collaboration *et al.* Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. *Lancet* **373**, 1849–1860 (2009).
2. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. *Lancet* **348**, 1329–39 (1996).
3. Bhatt, D. L. *et al.* Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events. *N. Engl. J. Med.* **354**, 1706–1717 (2006).
4. Bonaca, M. P. *et al.* Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction. *N. Engl. J. Med.* **372**, 1791–1800 (2015).
5. Morrow, D. A. *et al.* Vorapaxar in the Secondary Prevention of Atherothrombotic Events. *N. Engl. J. Med.* **366**, 1404–1413 (2012).
6. Bhatt, D. L. *et al.* International Prevalence, Recognition, and Treatment of Cardiovascular Risk Factors in Outpatients With Atherothrombosis. *JAMA* **295**, 180 (2006).
7. Steg, P. G. *et al.* One-year cardiovascular event rates in outpatients with atherothrombosis. *JAMA* **297**, 1197–206 (2007).
8. Libby, P. *et al.* Inflammation, Immunity, and Infection in Atherothrombosis. *J. Am. Coll. Cardiol.* **72**, 2071–2081 (2018).
9. Fox, K. A. A., Metra, M., Morais, J. & Atar, D. The myth of 'stable' coronary artery disease. *Nat. Rev. Cardiol.* (2019). doi:10.1038/s41569-019-0233-y
10. Roffi, M. *et al.* 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. *Eur. Heart J.* **37**, 267–315 (2016).

11. Ibanez, B. *et al.* 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. *Eur. Heart J.* (2017).  
doi:10.1093/eurheartj/ehx393
12. Valgimigli, M. *et al.* 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. *Eur. Heart J.* **39**, 213–260 (2018).
13. Aboyans, V. *et al.* 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). *Eur. Heart J.* (2017). doi:10.1093/eurheartj/ehx095
14. Arnett, D. K. *et al.* 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease. *Circulation* CIR00000000000000678 (2019). doi:10.1161/CIR.00000000000000678
15. Gerhard-Herman, M. D. *et al.* 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *J. Am. Coll. Cardiol.* **69**, e71–e126 (2017).
16. Knuuti, J. *et al.* 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. *Eur. Heart J.* (2019). doi:10.1093/eurheartj/ehz425
17. Piepoli, M. F. *et al.* 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representati. *Eur. Heart J.* **37**, 2315–2381 (2016).
18. Gaziano, J. M. *et al.* Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. *Lancet* **392**, 1036–1046 (2018).
19. ASCEND Study Collaborative Group *et al.* Effects of Aspirin for Primary Prevention in

- Persons with Diabetes Mellitus. *N. Engl. J. Med.* **379**, 1529–1539 (2018).
20. McNeil, J. J. *et al.* Effect of Aspirin on All-Cause Mortality in the Healthy Elderly. *N. Engl. J. Med.* **379**, 1519–1528 (2018).
  21. Zheng, S. L. & Roddick, A. J. Association of Aspirin Use for Primary Prevention With Cardiovascular Events and Bleeding Events: A Systematic Review and Meta-analysis. *JAMA* **321**, 277–287 (2019).
  22. Montalescot, G. A farewell to aspirin in primary prevention? *Nat. Rev. Cardiol.* **16**, 76–77 (2019).
  23. Mahmoud, A. N., Gad, M. M., Elgendy, A. Y., Elgendy, I. Y. & Bavry, A. A. Efficacy and safety of aspirin for primary prevention of cardiovascular events: a meta-analysis and trial sequential analysis of randomized controlled trials. *Eur. Heart J.* **40**, 607–617 (2019).
  24. Capodanno, D. Oral antithrombotic therapy after acute coronary syndromes: ‘Dual antiplatelet’ or ‘dual pathway’? *EuroIntervention* **13**, (2017).
  25. ten Cate, H. Tissue factor-driven thrombin generation and inflammation in atherosclerosis. *Thromb. Res.* **129 Suppl**, S38-40 (2012).
  26. Esmon, C. T. Targeting factor Xa and thrombin: impact on coagulation and beyond. *Thromb. Haemost.* **111**, 625–33 (2014).
  27. Borisssoff, J. I., Spronk, H. M. H. & ten Cate, H. The hemostatic system as a modulator of atherosclerosis. *N. Engl. J. Med.* **364**, 1746–60 (2011).
  28. Angiolillo, D. J., Capodanno, D. & Goto, S. Platelet thrombin receptor antagonism and atherothrombosis. *Eur. Heart J.* **31**, 17–28 (2010).
  29. Mostowik, M., Siniarski, A., Gołębiowska-Wiatrak, R., Nessler, J. & Gajos, G. Prolonged CRP Increase After Percutaneous Coronary Intervention Is Associated with High Thrombin Concentrations and Low Platelet’ Response to Clopidogrel in Patients with Stable Angina.

30. Brummel-Ziedins, K. *et al.* Thrombin generation in acute coronary syndrome and stable coronary artery disease: dependence on plasma factor composition. *J. Thromb. Haemost.* **6**, 104–10 (2008).
31. Becker, E. M. *et al.* Effects of rivaroxaban, acetylsalicylic acid and clopidogrel as monotherapy and in combination in a porcine model of stent thrombosis. *J. Thromb. Haemost.* **10**, 2470–80 (2012).
32. Perzborn, E., Heitmeier, S. & Laux, V. Effects of Rivaroxaban on Platelet Activation and Platelet-Coagulation Pathway Interaction: In Vitro and In Vivo Studies. *J. Cardiovasc. Pharmacol. Ther.* **20**, 554–62 (2015).
33. Álvarez, E., Paradela-Dobarro, B., Raposeiras-Roubín, S. & González-Juanatey, J. R. Protective, repairing and fibrinolytic effects of rivaroxaban on vascular endothelium. *Br. J. Clin. Pharmacol.* **84**, 280–291 (2018).
34. Andreotti, F., Testa, L., Biondi-Zoccai, G. G. L. & Crea, F. Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: An updated and comprehensive meta-analysis of 25 307 patients. *Eur. Heart J.* **27**, 519–526 (2006).
35. Kirchhof, P. *et al.* 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. *Eur. Heart J.* **37**, 2893–2962 (2016).
36. Sardar, P. *et al.* New oral anticoagulants are not superior to warfarin in secondary prevention of stroke or transient ischemic attacks, but lower the risk of intracranial bleeding: insights from a meta-analysis and indirect treatment comparisons. *PLoS One* **8**, e77694 (2013).
37. Wallentin, L. *et al.* Oral ximelagatran for secondary prophylaxis after myocardial infarction: The ESTEEM randomised controlled trial. *Lancet* **362**, 789–797 (2003).
38. Oldgren, J. *et al.* Dabigatran vs. placebo in patients with acute coronary syndromes on dual

- antiplatelet therapy: a randomized, double-blind, phase II trial. *Eur Hear. J* **32**, 2781–2789 (2011).
39. Steg, P. G. *et al.* RUBY-1: A randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome. *Eur. Heart J.* **32**, 2541–2554 (2011).
  40. Goldstein, S. *et al.* Phase 2 study of TAK-442, an oral factor Xa inhibitor, in patients following acute coronary syndrome. *Thrombosis and Haemostasis* 1141–1152 (2014). doi:10.1160/TH13-07-0543
  41. APPRAISE Steering Committee and Investigators *et al.* Apixaban, an Oral, Direct, Selective Factor Xa Inhibitor, in Combination With Antiplatelet Therapy After Acute Coronary Syndrome: Results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) Trial. *Circulation* **119**, 2877–2885 (2009).
  42. Alexander, J. H. *et al.* Apixaban with antiplatelet therapy after acute coronary syndrome. *N. Engl. J. Med.* **365**, 699–708 (2011).
  43. Mega, J. L. *et al.* Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. *Lancet* **374**, 29–38 (2009).
  44. Mega, J. L. *et al.* Rivaroxaban in patients with a recent acute coronary syndrome. *N. Engl. J. Med.* **366**, 9–19 (2012).
  45. Gibson, W. J. *et al.* Safety and Efficacy of Rivaroxaban When Added to Aspirin Monotherapy Among Stabilized Post-Acute Coronary Syndrome Patients: A Pooled Analysis Study of ATLAS ACS-TIMI 46 and ATLAS ACS 2-TIMI 51. *J. Am. Heart Assoc.* **8**, (2019).
  46. Ohman, E. M. *et al.* Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): A double-

- blind, multicentre, randomised trial. *Lancet* **389**, 1799–1808 (2017).
47. Capodanno, D. *et al.* Management of Antithrombotic Therapy in Atrial Fibrillation Patients Undergoing PCI: JACC State-of-the-Art Review. *J. Am. Coll. Cardiol.* **74**, 83–99 (2019).
  48. Dewilde WJ, Oirbans T, Verheugt FW, Kelder JC, De Smet BJ, H. J. & Adriaenssens T, Vrolix M, Heestermans AA, Vis MM, Tijssen JG, van 't Hof AW, ten B. J. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: An open-label, randomised, controlled trial. *Lancet* **381**, 1107–1115 (2013).
  49. Capodanno, D. *et al.* Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention. *Nat. Rev. Cardiol.* **15**, 480–496 (2018).
  50. Gibson CM, Mehran R, Bode C, Halperin J, Verheugt FW, W. P., Birmingham M, Iancu J, Burton P, van Eickels M, Korjian S, Daaboul Y, L. G. & Cohen M, Husted S, Peterson ED, F. K. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. *N Engl J Med* **375**, 2423–2434 (2016).
  51. Gibson, C. M. *et al.* Recurrent Hospitalization Among Patients With Atrial Fibrillation Undergoing Intracoronary Stenting Treated With 2 Treatment Strategies of Rivaroxaban or a Dose-Adjusted Oral Vitamin K Antagonist Treatment StrategyClinical Perspective. *Circulation* **135**, 323–333 (2017).
  52. Cannon, C. P. *et al.* Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. *N. Engl. J. Med.* **377**, 1513–1524 (2017).
  53. Lopes, R. D. *et al.* Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation. *N. Engl. J. Med.* NEJMoa1817083 (2019). doi:10.1056/NEJMoa1817083
  54. Vranckx, P. *et al.* Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF

- PCI): a randomised, open-label, phase 3b trial. *Lancet* (2019). doi:10.1016/S0140-6736(19)31872-0
55. Capodanno, D. & Angiolillo, D. J. Dual antithrombotic therapy for atrial fibrillation and PCI. *Lancet* (2019). doi:10.1016/S0140-6736(19)31954-3
  56. Franchi, F. *et al.* Effects of Edoxaban on the Cellular and Protein Phase of Coagulation in Patients with Coronary Artery Disease on Dual Antiplatelet Therapy with Aspirin and Clopidogrel: Results of the EDOX-APT Study. *Thromb. Haemost.* (2019). doi:10.1055/s-0039-1695772
  57. Golwala, H. B. *et al.* Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials. *Eur. Heart J.* **39**, 1726-1735a (2018).
  58. Lopes, R. D. *et al.* Safety and Efficacy of Antithrombotic Strategies in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Network Meta-analysis of Randomized Controlled Trials. *JAMA Cardiol.* (2019). doi:10.1001/jamacardio.2019.1880
  59. Eikelboom, J. W. *et al.* Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. *N. Engl. J. Med.* **377**, 1319–1330 (2017).
  60. Sharma, M. *et al.* Stroke Outcomes in the COMPASS Trial. *Circulation* **139**, 1134–1145 (2019).
  61. Moayyedi, P. *et al.* Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin. *Gastroenterology* **157**, 682-691.e2 (2019).
  62. Moayyedi, P. *et al.* Pantoprazole to Prevent Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled Trial. *Gastroenterology* **157**, 403-412.e5 (2019).

63. Anand, S. S. *et al.* Rivaroxaban Plus Aspirin Versus Aspirin in Relation to Vascular Risk in the COMPASS Trial. *J. Am. Coll. Cardiol.* **73**, 3271–3280 (2019).
64. Branch, K. R. *et al.* Rivaroxaban With or Without Aspirin in Patients with Heart Failure and Chronic Coronary or Peripheral Artery Disease: The COMPASS Trial. *Circulation* (2019). doi:10.1161/CIRCULATIONAHA.119.039609
65. Fox, K. A. A. *et al.* Rivaroxaban Plus Aspirin in Patients With Vascular Disease and Renal Dysfunction: From the COMPASS Trial. *J. Am. Coll. Cardiol.* **73**, 2243–2250 (2019).
66. Connolly SJ, Eikelboom JW, Bosch J, Dagenais G, Dyal L, Lanas F, Metsarinne K, O'Donnell M, Dans AL, Ha JW, Parkhomenko AN, Avezum AA, Lonn E, Lisheng L, Torp-Pedersen C, Widimsky P, Maggioni AP, Felix C, Keltai K, Hori M, Yusoff K, Guzik TJ, Bhatt DL, Br. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. *Lancet* **391**, 205–218 (2018).
67. Lamy, A. *et al.* Rivaroxaban, Aspirin, or Both to Prevent Early Coronary Bypass Graft Occlusion: The COMPASS-CABG Study. *J. Am. Coll. Cardiol.* **73**, 121–130 (2019).
68. Anand, S. S. *et al.* Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. *Lancet* **391**, 219–229 (2018).
69. Anand, S. S. *et al.* Major Adverse Limb Events in Lower Extremity Peripheral Artery Disease: COMPASS Trial. *J. Am. Coll. Cardiol.* **71**, 2306–2315 (2018).
70. Borissoff, J. I., Spronk, H. M. H., Heeneman, S. & ten Cate, H. Is thrombin a key player in the 'coagulation-atherogenesis' maze? *Cardiovasc. Res.* **82**, 392–403 (2009).
71. Zannad, F. *et al.* Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease. *N. Engl. J. Med.* **379**, 1332–1342 (2018).

72. Greenberg, B. *et al.* Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm: A Post Hoc Analysis of the COMMANDER HF Trial. *JAMA Cardiol.* (2019). doi:10.1001/jamacardio.2019.1049
73. Capodanno, D. & Angiolillo, D. J. Antithrombotic Therapy for Prevention of Cerebral Thromboembolic Events After Transcatheter Aortic Valve Replacement. *JACC Cardiovasc. Interv.* **10**, 1366–1369 (2017).
74. Windecker, S. *et al.* Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study. *Am. Heart J.* **184**, 81–87 (2017).
75. Collet, J.-P. *et al.* Oral anti-Xa anticoagulation after trans-aortic valve implantation for aortic stenosis: The randomized ATLANTIS trial. *Am. Heart J.* **200**, 44–50 (2018).
76. Van Mieghem, N. M. *et al.* Edoxaban Versus standard of care and their effects on clinical outcomes in patients having undergone Transcatheter Aortic Valve Implantation in Atrial Fibrillation—Rationale and design of the ENVISAGE-TAVI AF trial. *Am. Heart J.* **205**, 63–69 (2018).
77. Capodanno, D., Alfonso, F., Levine, G. N., Valgimigli, M. & Angiolillo, D. J. Dual Antiplatelet Therapy: Appraisal of the ACC/AHA and ESC Focused Updates. *J Am Coll Cardiol* **72**, 103–119 (2018).
78. Zeymer, U., Schrage, B. & Westermann, D. Dual Pathway Inhibition with Low-Dose Direct Factor Xa Inhibition after Acute Coronary Syndromes-Why Is It Not Used in Clinical Practice? *Thromb. Haemost.* **118**, 1528–1534 (2018).
79. Angiolillo, D. J. *et al.* Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention. *Circulation* **138**, 527–536 (2018).

80. Capodanno, D. *et al.* Management of Antithrombotic Therapy in Atrial Fibrillation Patients Undergoing PCI: JACC State-of-the-Art Review. *J Am Coll Cardiol* In press (2019).
81. Lip, G. Y. H. *et al.* 2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the Europ. *Europace* **21**, 192–193 (2019).
82. Matsumura-Nakano, Y. *et al.* Open-Label Randomized Trial Comparing Oral Anticoagulation With and Without Single Antiplatelet Therapy in Patients With Atrial Fibrillation and Stable Coronary Artery Disease Beyond 1 Year After Coronary Stent Implantation. *Circulation* **139**, 604–616 (2019).
83. Yasuda, S. *et al.* Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease. *N. Engl. J. Med.* NEJMoa1904143 (2019). doi:10.1056/NEJMoa1904143
84. van Rein, N. *et al.* Major Bleeding Rates in Atrial Fibrillation Patients on Single, Dual, or Triple Antithrombotic Therapy. *Circulation* **139**, 775–786 (2019).
85. Angiolillo, D. J. *et al.* Variability in Individual Responsiveness to Clopidogrel. *J. Am. Coll. Cardiol.* **49**, 1505–1516 (2007).
86. Fox, K. A. A. *et al.* Anti-thrombotic options for secondary prevention in patients with chronic atherosclerotic vascular disease: what does COMPASS add? *Eur. Heart J.* (2018). doi:10.1093/eurheartj/ehy347
87. Darmon, A. *et al.* External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry. *Eur. Heart J.* **39**, 750-757a (2018).
88. Hussain, M. A. *et al.* Antithrombotic Therapy for Peripheral Artery Disease: Recent Advances. *J. Am. Coll. Cardiol.* **71**, 2450–2467 (2018).

89. Boden, W. E. & Bhatt, D. L. Will COMPASS Point to a New Direction in Thrombotic Risk Reduction in Patients With Stable Cardiovascular Disease? *Circulation* **138**, 858–860 (2018).
90. Sumaya, W., Geisler, T., Kristensen, S. D. & Storey, R. F. Dual Antiplatelet or Dual Antithrombotic Therapy for Secondary Prevention in High-Risk Patients with Stable Coronary Artery Disease? *Thromb. Haemost.* (2019). doi:10.1055/s-0039-1679903
91. Hiatt, W. R. *et al.* Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease. **376**, 32–40 (2017).
92. Cacoub, P. P. *et al.* Patients with peripheral arterial disease in the CHARISMA trial. *Eur. Heart J.* **30**, 192–201 (2009).
93. Bonaca, M. P. *et al.* Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease. *J. Am. Coll. Cardiol.* **67**, 2719–2728 (2016).
94. Bonaca, M. P. *et al.* Vorapaxar in patients with peripheral artery disease: results from TRA2{degrees}P-TIMI 50. *Circulation* **127**, 1522–9, 1529e1-6 (2013).